| 1. |
- Gunduz, C., et al.
(author)
-
Hyperlipidaemia prevalence and cholesterol control in obstructive sleep apnoea: Data from the European sleep apnea database (ESADA)
- 2019
-
In: Journal of Internal Medicine. - : Wiley. - 0954-6820 .- 1365-2796. ; 286:6, s. 676-688
-
Journal article (peer-reviewed)abstract
- Background and objective Obstructive sleep apnoea (OSA) and hyperlipidaemia are independent risk factors for cardiovascular disease. This study investigates the association between OSA and prevalence of hyperlipidaemia in patients of the European Sleep Apnea Database (ESADA) cohort. Methods The cross-sectional analysis included 11 892 patients (age 51.9 +/- 12.5 years, 70% male, body mass index (BMI) 31.3 +/- 6.6 kg/m(2), mean oxygen desaturation index (ODI) 23.7 +/- 25.5 events/h) investigated for OSA. The independent odds ratio (OR) for hyperlipidaemia in relation to measures of OSA (ODI, apnoea-hypopnoea index, mean and lowest oxygen saturation) was determined by means of general linear model analysis with adjustment for important confounders such as age, BMI, comorbidities and study site. Results Hyperlipidaemia prevalence increased from 15.1% in subjects without OSA to 26.1% in those with severe OSA, P < 0.001. Corresponding numbers in patients with diabetes were 8.5% and 41.5%, P < 0.001. Compared with ODI quartile I, patients in ODI quartiles II-IV had an adjusted OR (95% CI) of 1.33 (1.15-1.55), 1.37 (1.17-1.61) and 1.33 (1.12-1.58) (P < 0.001), respectively, for hyperlipidaemia. Obesity was defined as a significant risk factor for hyperlipidaemia. Subgroups of OSA patients with cardio-metabolic comorbidities demonstrated higher prevalence of HL. In addition, differences in hyperlipidaemia prevalence were reported in European geographical regions with the highest prevalence in Central Europe. Conclusion Obstructive sleep apnoea, in particular intermittent hypoxia, was independently associated with the prevalence of hyperlipidaemia diagnosis.
|
|
| 2. |
- Gunduz, C., et al.
(author)
-
Long-term positive airway pressure therapy is associated with reduced total cholesterol levels in patients with obstructive sleep apnea: data from the European Sleep Apnea Database (ESADA)
- 2020
-
In: Sleep Medicine. - : Elsevier BV. - 1389-9457. ; 75, s. 201-209
-
Journal article (peer-reviewed)abstract
- Background and aim: Obstructive sleep apnea (OSA) is an independent risk factor for dyslipidemia. The current study examined the effects of positive airway pressure (PAP) treatment on lipid status in the European Sleep Apnea Database (ESADA). Methods: The prospective cohort study enrolled 1564 OSA subjects (74% male, mean age 54 ± 11y, body mass index (BMI) 32.7 ± 6.6 kg/m2 and apnea-hypopnea index (AHI) 40.3 ± 24.4 n/h) undergoing PAP therapy for at least three months (mean 377.6 ± 419.5 days). Baseline and follow-up total cholesterol (TC) from nine centers were analyzed. Repeated measures and logistic regression tests (adjusted for age, sex, weight changes, lipid lowering medication, PAP compliance, and treatment duration) were used to compare changes in TC concentration. Incident risk for a coronary heart disease event (CHD) was used to compute a Framingham CHD risk score (estimated from age, BMI, blood pressure, and TC). Results: Adjusted means of TC decreased from 194.2 mg/dl to 189.3 mg/dl during follow-up (p = 0.019). A clinically significant (10%) reduction of TC at PAP follow-up was observed in 422 patients (27%). Duration of PAP therapy was identified as independent predictor for TC reduction, which implies an approximately 10% risk reduction for incident CHD events (from 26.7% to 24.1% in men and from 11.2% to 10.1% in women, p < 0.001 respectively). Conclusion: This observational study demonstrates a reduction of TC after long-term PAP treatment. The close association between TC concentration and cardiovascular (CV) mortality suggests that identification and treatment of OSA may have a beneficial effect on overall CV risk due to this mechanism. This possibility needs to be evaluated in prospective randomized studies. © 2020 Elsevier B.V.
|
|
| 3. |
- Bundschuh, Jochen, et al.
(author)
-
Naturally occurring arsenic in terrestrial geothermal systems of western Anatolia, Turkey : Potential role in contamination of freshwater resources
- 2013
-
In: Journal of Hazardous Materials. - : Elsevier BV. - 0304-3894 .- 1873-3336. ; 262, s. 951-959
-
Journal article (peer-reviewed)abstract
- Arsenic (As) contamination in terrestrial geothermal systems has been identified in many countries worldwide. Concentrations higher than 0.01mg/L are detrimental to human health. We examined potential consequences for As contamination of freshwater resources based on hydrogeochemical investigations of geothermal waters in deep wells and hot springs collected from western Anatolia, Turkey. We analyzed samples for major ions and trace element concentrations. Temperature of geothermal waters in deep wells showed extreme ranges (40 and 230°C), while, temperature of hot spring fluids was up to 90°C. The Piper plot illustrated two dominant water types: Na-HCO3 - type for geothermal waters in deep wells and Ca-HCO3 - type for hot spring fluids. Arsenic concentration ranged from 0.03 to 1.5mg/L. Dominance of reduced As species, i.e., As(III), was observed in our samples. The Eh value ranged between -250 and 119mV, which suggests diverse geochemical conditions. Some of the measured trace elements were found above the World Health Organization guidelines and Turkish national safe drinking water limits. The variation in pH (range: 6.4-9.3) and As in geothermal waters suggest mixing with groundwater. Mixing of geothermal waters is primarily responsible for contamination of freshwater resources and making them unsuitable for drinking or irrigation.
|
|
| 4. |
- Chen, C. -Y, et al.
(author)
-
Occurrence of arsenic and related microbial signature of hydrothermal systems in Western Turkey
- 2012
-
In: Understanding the Geological and Medical Interface of Arsenic, As 2012 - 4th International Congress: Arsenic in the Environment. - : CRC Press. - 9780415637633 ; , s. 486-488
-
Conference paper (peer-reviewed)abstract
- The naturally occurring aqueous Arsenic (As) and other toxic elements are found around the world. The present study concentrates on arsenic concentrations, speciation and related microbial diversity in a hydrothermal system in Western Turkey. The surface temperatures of hot springs reach up to 90°C and deep well (reservoir) temperatures vary in the range of 40 to 230°C. The elements such as As, B, Br, Ba, Cr, Fe, Mn, V and Zn are found in high concentration in hydrothermal waters. Hydrogeochemically, Seferihisar hot spring exhibited a Na-Cl water type. On the other hand, Karahayit, Pamukkale, Emirfaki, Alaşehir and Sart exhibit a Ca-HCO 3 water type and Çitgöl exhibited a Na-HCO 3-SO 4 water type. The arsenic (As) concentrations in geothermal waters of Western Anatolia have been detected to range from 0.03 mg/L to 1.5 mg/L, including Buharkent (İnalti) (1.50 ± 0.005 mg/L), Kizildere (1.13 ± 0.005 mg/L), Eynal (0.71 ± 0.005 mg/L) and Sarayköy (0.06 ± 0.004 mg/L). Arsenic (III) is the dominant species in geothermal water of Western Anatolia. The 16S rRNA gene sequences of bacterial diversity show that the thermophilic, sulfur/thiosulfate-oxidizing bacterium (Thiobacter subterraneus) is present in Kula geothermal water and mesophilic sulfur- and thiosulfate-oxidizing Sulfurovum lithotrophicum bacterium occurs in Sarayköy geothermal spring. Also, Bacillus fumarioli, (a thermophilic, aerobic endospore forming bacterium growing on (NH 4) 2 SO 4, MgSO 4 and MnSO 4 at 50-55°C), Schlegelella thermodepolymerans and Methylocaldum szegediense are rich in geothermal water.
|
|
| 5. |
- Edwards, Robert A., et al.
(author)
-
Global phylogeography and ancient evolution of the widespread human gut virus crAssphage
- 2019
-
In: Nature Microbiology. - : Springer Science and Business Media LLC. - 2058-5276. ; 4:10, s. 1727-1736
-
Journal article (peer-reviewed)abstract
- Microbiomes are vast communities of microorganisms and viruses that populate all natural ecosystems. Viruses have been considered to be the most variable component of microbiomes, as supported by virome surveys and examples of high genomic mosaicism. However, recent evidence suggests that the human gut virome is remarkably stable compared with that of other environments. Here, we investigate the origin, evolution and epidemiology of crAssphage, a widespread human gut virus. Through a global collaboration, we obtained DNA sequences of crAssphage from more than one-third of the world's countries and showed that the phylogeography of crAssphage is locally clustered within countries, cities and individuals. We also found fully colinear crAssphage-like genomes in both Old-World and New-World primates, suggesting that the association of crAssphage with primates may be millions of years old. Finally, by exploiting a large cohort of more than 1,000 individuals, we tested whether crAssphage is associated with bacterial taxonomic groups of the gut microbiome, diverse human health parameters and a wide range of dietary factors. We identified strong correlations with different clades of bacteria that are related to Bacteroidetes and weak associations with several diet categories, but no significant association with health or disease. We conclude that crAssphage is a benign cosmopolitan virus that may have coevolved with the human lineage and is an integral part of the normal human gut virome.
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
- Ørnbjerg, L. M., et al.
(author)
-
Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration
- 2022
-
In: Seminars in Arthritis and Rheumatism. - : Elsevier BV. - 0049-0172 .- 1532-866X. ; 56
-
Journal article (peer-reviewed)abstract
- Objectives: In patients with axial spondyloarthritis (axSpA) initiating their first tumor necrosis factor alpha-inhibitor (TNFi), we aimed to identify common baseline predictors of Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) inactive disease (primary objective) and clinically important improvement (CII) at 6 months, and drug retention at 12-months across 15 European registries. Methods: Baseline demographic and clinical characteristics were collected. Outcomes were investigated per registry and in pooled data using logistic regression analyses on multiply imputed data. Results: The consistency of baseline predictors in individual registries justified pooling the data. In the pooled dataset (n = 21,196), the 6-month rates for ASDAS inactive disease and ASDAS CII were 26% and 51%, and the 12-month drug retention rate 65% in patients with available data (n = 9,845, n = 6,948 and n = 21,196, respectively). Nine common baseline predictors of ASDAS inactive disease, ASDAS CII and 12-month drug retention were identified, and the odds ratios (95%-confidence interval) for ASDAS inactive disease were: age, per year: 0.97 (0.97–0.98), men vs. women: 1.88 (1.60–2.22), current vs. non-smoking: 0.76 (0.63–0.91), HLA-B27 positive vs. negative: 1.51 (1.20–1.91), TNF start year 2015–2018 vs. 2009–2014: 1.24 (1.06–1.45), CRP>10 vs. ≤10 mg/l: 1.49 (1.25–1.77), one unit increase in health assessment questionnaire (HAQ): 0.77 (0.58–1.03), one-millimeter (mm) increase in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) fatigue and spinal pain: 0.99 (0.99–1.00) and 0.99 (0.99–1.99), respectively Conclusion: Common baseline predictors of treatment response and adherence to TNFi could be identified across data from 15 European registries, indicating that they may be universal across different axSpA populations.
|
|
